MOG and neoplasm: In GBM specifically, Choe et al. engineered SynNotch-CAR T-cells against EGFRvIII or myelin oligodendrocyte glycoprotein (MOG) as priming antigens, ensuring that the T cells localised to EGFRvIII- or MOG-expressing GBM tumours [244].